Elevating the Therapeutic Potential of Antibody-Drug Conjugates in Cancer and Beyond
At Spirea, we are revolutionising healthcare with our unique multivalent ELIVATE linker technology. Our mission is to enable next generation ADCs that address critical unmet needs in oncology and other diseases.
ABOUT US
Spirea is focused on elevating the therapeutic potential of ADCs in cancer and beyond
Our unique ELIVATE linker technology will significantly expand the accessible payload repertoire to power the next generation of ADCs. With ELIVATE, we will fully leverage and optimise the benefits of incorporating payloads with a broad variety of therapeutic modes-of-action.
We are currently working to exemplify our ELIVATE linker technology and develop proprietary and differentiated linker payloads ready for partnering and in-house ADC development. Spirea’s ELIVATE technology is attracting strong interest from pharma partners which will be a source of significant company value as Spirea expands its portfolio.
Our dedicated team of experts is committed to unlocking the full potential of ADCs with our unique multivalent ELIVATE linker platform. By significantly improving patient outcomes in cancer and beyond, we aim to generate substantial shareholder value and deliver better therapies for patients worldwide.
Elevating the Potential of ADCs
Our Technology
Spirea’s ELIVATE ADC linker technology has been expertly engineered for precision
ELIVATE, developed by Dr. Myriam Ouberai, Spirea’s Founder, aims to unlock the significant potential of ADCs in cancer and beyond. Using her broad expertise in engineering large, complex biomolecules, gained at the University of Cambridge, Dr. Ouberai has addressed various critical drug delivery challenges. This has paved the way for Spirea’s innovative, multivalent ELIVATE linker technology, enhancing the therapeutic potential of ADCs by:
- Accessing a much broader payload repertoire: Central to ADCs achieving their therapeutic potential in cancer and beyond.
- Allowing much higher payload loading: Optimising the therapeutic potential of ADCs by incorporating tailored payloads to better address multiple indications.
- Ensuring excellent drug pharmacokinetics: Achieving a long half-life and improved bioavailability.
- Achieving precise drug delivery: Ensuring targeted action at the cellular level for optimal therapeutic outcomes.
ELIVATE based ADCs with different payloads have shown
In Vivo Efficacy
Tumour regression and complete response achieved in mouse xenograft models
Physicochemical Profile
High monomeric purity
Pharmacokinetics
Excellent half-life
Stability
Tolerability
Good rodent tolerability profiles at high dose
The potential for ADCs to transform cancer treatment has been constrained by the limited number of payloads that can be utilised. I believe Myriam and her team have the solution to create the next generation of ADCs and make a significant impact for cancer patients worldwide.”
Dr Anthony Tolcher, Founder & CEO, NEXT Oncology
PARTNERING
Spirea’s highly differentiated ELIVATE linker technology
is generating significant interest from potential ADC partners
Partners can explore the feasibility of combining our ELIVATE linker technology with their payloads and antibodies, facilitating a streamlined pathway to collaboration.
Spirea provides access to its advanced expertise and support in ADC design, linker-payload construction, and antibody conjugation, utilising our proprietary linker with both validated and novel payloads.
We are keen to partner with a broad range of well-resourced companies, with a line-of-sight to approved products, including:
- ADC oncology companies seeking alternatives to Topo-1 inhibitors to widen the therapeutic index, evade resistance, and improve clinical positioning.
- Small molecule (SM) oncology companies aiming to convert standalone small molecules to targeted ADCs.
- Degrader/molecule glue oncology companies seeking better targeting and cell delivery of their active agents.
- Antibody therapeutics (oncology) companies wanting enhanced cell killing activity by converting their naked antibody to an ADC.
- Inflammation and autoimmunity companies targeting the delivery of small molecule therapeutics to specific cell populations.
Spirea’s ability to accelerate the ADC development process empowers partners to achieve their therapeutic goals by creating superior ADCs with our cutting-edge technology and expertise.
OUR TEAM
Dr Bo Rode Hansen
News
Spirea announces the promotion of Dr Ludovic Juen to Principal Scientist as the company continues to advance its proprietary technology in next-generation ADCs
Spirea welcomes Dr Bo Rode Hansen as Executive Director as the company further strengthens its management and business capabilities
CONTACT US
We are always very interested in speaking with potential investors, partners, and collaborators. Please do get in touch.
Scientific Advisory Board
Professor John Hartley
Dr Anthony Tolcher
Dr Rakesh Dixit
Dr Paul Varley
Board
Supported By
